Cargando…
The Glucose-lowering Efficacy of Sitagliptin in Obese Japanese Patients with Type 2 Diabetes
Objective Dipeptidyl peptidase-4 (DPP-4) inhibitors are the most frequently prescribed oral hypoglycemic agents in Japan. Although a relationship between the efficacy of DPP-4 inhibitors and the body mass index (BMI) has been reported, this relationship is controversial. We investigated whether the...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Japanese Society of Internal Medicine
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5410467/ https://www.ncbi.nlm.nih.gov/pubmed/28321057 |
_version_ | 1783232684158353408 |
---|---|
author | Kodera, Ryo Shikata, Kenichi Nakamura, Akihiko Okazaki, Satoru Nagase, Ryo Nakatou, Tatsuaki Haisa, Shigeru Hida, Kazuyuki Miyashita, Katsuhiro Makino, Hirofumi |
author_facet | Kodera, Ryo Shikata, Kenichi Nakamura, Akihiko Okazaki, Satoru Nagase, Ryo Nakatou, Tatsuaki Haisa, Shigeru Hida, Kazuyuki Miyashita, Katsuhiro Makino, Hirofumi |
author_sort | Kodera, Ryo |
collection | PubMed |
description | Objective Dipeptidyl peptidase-4 (DPP-4) inhibitors are the most frequently prescribed oral hypoglycemic agents in Japan. Although a relationship between the efficacy of DPP-4 inhibitors and the body mass index (BMI) has been reported, this relationship is controversial. We investigated whether the BMI value affects the glucose-lowering efficacy of sitagliptin in obese Japanese patients with type 2 diabetes. Methods One hundred sixty-two outpatients with inadequate glycemic control were divided into four groups based on their baseline BMI values. They were then treated with sitagliptin (a DPP-4 inhibitor) for 3 months and followed-up for 12 months. Results Sitagliptin significantly reduced the hemoglobin A1c level (HbA1c: -0.71±0.55%) after 3 months, and continued to reduce the HbA1c level until 12 months. There was no significant difference in the efficacy of sitagliptin among the four BMI groups. A multiple linear regression analysis indicated that the factors contributing to the change in the HbA1c level were the baseline level of HbA1c and the homeostasis model assessment of β-cell function (HOMA-β). In terms of the relationship between the baseline BMI value and the efficacy of sitagliptin treatment, the number of patients who responded to sitagliptin treatment after 3 months was lowest in the group of patients with the highest BMI values. A multiple logistic regression analysis revealed that the baseline HOMA-β function and HbA1c level and a baseline BMI value of ≥30 kg/m(2) significantly contributed to the response to sitagliptin treatment. Conclusion The results indicated that sitagliptin treatment was effective in controlling glucose metabolism disorder in obese Japanese patients with type 2 diabetes. However, the efficacy of sitagliptin treatment might be attenuated in severely obese patients, such as those with a BMI value of ≥30 kg/m(2). |
format | Online Article Text |
id | pubmed-5410467 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | The Japanese Society of Internal Medicine |
record_format | MEDLINE/PubMed |
spelling | pubmed-54104672017-05-15 The Glucose-lowering Efficacy of Sitagliptin in Obese Japanese Patients with Type 2 Diabetes Kodera, Ryo Shikata, Kenichi Nakamura, Akihiko Okazaki, Satoru Nagase, Ryo Nakatou, Tatsuaki Haisa, Shigeru Hida, Kazuyuki Miyashita, Katsuhiro Makino, Hirofumi Intern Med Original Article Objective Dipeptidyl peptidase-4 (DPP-4) inhibitors are the most frequently prescribed oral hypoglycemic agents in Japan. Although a relationship between the efficacy of DPP-4 inhibitors and the body mass index (BMI) has been reported, this relationship is controversial. We investigated whether the BMI value affects the glucose-lowering efficacy of sitagliptin in obese Japanese patients with type 2 diabetes. Methods One hundred sixty-two outpatients with inadequate glycemic control were divided into four groups based on their baseline BMI values. They were then treated with sitagliptin (a DPP-4 inhibitor) for 3 months and followed-up for 12 months. Results Sitagliptin significantly reduced the hemoglobin A1c level (HbA1c: -0.71±0.55%) after 3 months, and continued to reduce the HbA1c level until 12 months. There was no significant difference in the efficacy of sitagliptin among the four BMI groups. A multiple linear regression analysis indicated that the factors contributing to the change in the HbA1c level were the baseline level of HbA1c and the homeostasis model assessment of β-cell function (HOMA-β). In terms of the relationship between the baseline BMI value and the efficacy of sitagliptin treatment, the number of patients who responded to sitagliptin treatment after 3 months was lowest in the group of patients with the highest BMI values. A multiple logistic regression analysis revealed that the baseline HOMA-β function and HbA1c level and a baseline BMI value of ≥30 kg/m(2) significantly contributed to the response to sitagliptin treatment. Conclusion The results indicated that sitagliptin treatment was effective in controlling glucose metabolism disorder in obese Japanese patients with type 2 diabetes. However, the efficacy of sitagliptin treatment might be attenuated in severely obese patients, such as those with a BMI value of ≥30 kg/m(2). The Japanese Society of Internal Medicine 2017-03-15 /pmc/articles/PMC5410467/ /pubmed/28321057 Text en https://creativecommons.org/licenses/by-nc-nd/4.0/ The Internal Medicine is an Open Access article distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view the details of this license, please visit (https://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Original Article Kodera, Ryo Shikata, Kenichi Nakamura, Akihiko Okazaki, Satoru Nagase, Ryo Nakatou, Tatsuaki Haisa, Shigeru Hida, Kazuyuki Miyashita, Katsuhiro Makino, Hirofumi The Glucose-lowering Efficacy of Sitagliptin in Obese Japanese Patients with Type 2 Diabetes |
title | The Glucose-lowering Efficacy of Sitagliptin in Obese Japanese Patients with Type 2 Diabetes |
title_full | The Glucose-lowering Efficacy of Sitagliptin in Obese Japanese Patients with Type 2 Diabetes |
title_fullStr | The Glucose-lowering Efficacy of Sitagliptin in Obese Japanese Patients with Type 2 Diabetes |
title_full_unstemmed | The Glucose-lowering Efficacy of Sitagliptin in Obese Japanese Patients with Type 2 Diabetes |
title_short | The Glucose-lowering Efficacy of Sitagliptin in Obese Japanese Patients with Type 2 Diabetes |
title_sort | glucose-lowering efficacy of sitagliptin in obese japanese patients with type 2 diabetes |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5410467/ https://www.ncbi.nlm.nih.gov/pubmed/28321057 |
work_keys_str_mv | AT koderaryo theglucoseloweringefficacyofsitagliptininobesejapanesepatientswithtype2diabetes AT shikatakenichi theglucoseloweringefficacyofsitagliptininobesejapanesepatientswithtype2diabetes AT nakamuraakihiko theglucoseloweringefficacyofsitagliptininobesejapanesepatientswithtype2diabetes AT okazakisatoru theglucoseloweringefficacyofsitagliptininobesejapanesepatientswithtype2diabetes AT nagaseryo theglucoseloweringefficacyofsitagliptininobesejapanesepatientswithtype2diabetes AT nakatoutatsuaki theglucoseloweringefficacyofsitagliptininobesejapanesepatientswithtype2diabetes AT haisashigeru theglucoseloweringefficacyofsitagliptininobesejapanesepatientswithtype2diabetes AT hidakazuyuki theglucoseloweringefficacyofsitagliptininobesejapanesepatientswithtype2diabetes AT miyashitakatsuhiro theglucoseloweringefficacyofsitagliptininobesejapanesepatientswithtype2diabetes AT makinohirofumi theglucoseloweringefficacyofsitagliptininobesejapanesepatientswithtype2diabetes AT koderaryo glucoseloweringefficacyofsitagliptininobesejapanesepatientswithtype2diabetes AT shikatakenichi glucoseloweringefficacyofsitagliptininobesejapanesepatientswithtype2diabetes AT nakamuraakihiko glucoseloweringefficacyofsitagliptininobesejapanesepatientswithtype2diabetes AT okazakisatoru glucoseloweringefficacyofsitagliptininobesejapanesepatientswithtype2diabetes AT nagaseryo glucoseloweringefficacyofsitagliptininobesejapanesepatientswithtype2diabetes AT nakatoutatsuaki glucoseloweringefficacyofsitagliptininobesejapanesepatientswithtype2diabetes AT haisashigeru glucoseloweringefficacyofsitagliptininobesejapanesepatientswithtype2diabetes AT hidakazuyuki glucoseloweringefficacyofsitagliptininobesejapanesepatientswithtype2diabetes AT miyashitakatsuhiro glucoseloweringefficacyofsitagliptininobesejapanesepatientswithtype2diabetes AT makinohirofumi glucoseloweringefficacyofsitagliptininobesejapanesepatientswithtype2diabetes |